Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience.
48-month PSA
brachytherapy
long-term survival
low dose rate
prostate cancer
stage
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
30
07
2021
received:
04
05
2021
accepted:
25
08
2021
pubmed:
28
8
2021
medline:
1
6
2022
entrez:
27
8
2021
Statut:
ppublish
Résumé
To assess the long-term treatment efficacy of low-dose-rate (LDR) brachytherapy for the treatment of localized prostate cancer. Cause-of-death annotation in our prospective database was supplemented with death certificate information obtained via an internal audit of patients treated from 1999 to 2017 with LDR prostate brachytherapy as monotherapy or as combination with androgen deprivation therapy and/or external beam radiotherapy. Overall and disease-specific survival were the primary outcomes, estimated with Kaplan-Meier and competing risks multi-state models. Clinical variables influencing mortality were assessed with Cox proportional hazards regression in a sub-analysis of men to assess the predictive value of prostate-specific antigen (PSA) level at 48 months post implant. The audit process began in October 2017 and culminated in June 2020 with a curated series of 2936 patients. All-cause and prostate cancer-specific death prevalence were 11% and 2.9%, respectively. The median (range) follow-up time was 10 (3-21) years and the median (range) time to death from any cause was 9 (3-21) years. At 15 years post implant the overall and prostate cancer-specific survival probability were 81% and 95%, respectively. The 15-year cumulative incidence rates of death not due and due to prostate cancer were 14% and 5%, respectively. A greater risk of death due to prostate cancer was conferred by increasing age at therapy (hazard ratio [HR] 1.1, P < 0.001), advanced clinical stages relative to T1a-T2a (HR 1.9, P = 0.048 for T2b; HR 2.7, P = 0.023 for T2c-T3b) and a 48-month PSA level >1.0 ng/mL (HR 6.8, P < 0.001). This study constitutes the largest retrospective analyses of long-term mortality outcomes from prospectively collected prostate brachytherapy data and confirms the excellent treatment efficacy of LDR prostate brachytherapy for localized prostate cancer. T2 clinical stage subdivisions and 48-month PSA level >1.0 ng/mL appear to be strong indicators of prostate cancer-related survival.
Substances chimiques
Androgen Antagonists
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
723-730Informations de copyright
© 2021 The Authors BJU International © 2021 BJU International.
Références
NICE. Prostate cancer: diagnosis and treatment. Full guideline. 2014. https://www.nice.org.uk/guidance/cg175
Langley SE, Laing RW. 4D Brachytherapy, a novel real-time prostate brachytherapy technique using stranded and loose seeds. BJU Int 2012; 109(Suppl 1): 1-6
Langley SEM, Uribe J, Uribe-Lewis S et al. Comparative analysis of clinical outcomes and procedural costs between the conventional two-stage technique and 4D brachytherapy for early prostate cancer. Clin Oncol (R Coll Radiol) 2018; 30: 57-64
Laing R, Uribe J, Uribe-Lewis S et al. Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse. BJU Int 2018; 122: 610-7
Zelefsky MJ, Shasha D, Branco RD et al. Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer. J Urol 2014; 192: 868-74
Turner EL, Metcalfe C, Donovan JL et al. Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. Br J Cancer 2016; 115: 90-4
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing: 2020. http://www.R-project.org
Therneau TM. A Package for Survival Analysis in R. 2020. Available at: https://CRAN.R-project.org/package=survival
Therneau TM, Crowson C, Atkinson E. Multi-state models and competing risks. 2020. Available at: https://cran.r-project.org/web/packages/survival/vignettes/compete.pdf
Crook JM, Tang C, Thames H et al. A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol 2020; 149: 64-9
Uribe J, Uribe-Lewis S, Khaksar S et al. Low-dose-rate prostate brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure. BJUI Compass 2021; 2: 9-10
Goy BW, Burchette R, Soper MS, Chang T, Cosmatos HA. Ten-year treatment outcomes of radical prostatectomy vs external beam radiation therapy vs brachytherapy for 1503 patients with intermediate-risk prostate cancer. Urology 2020; 136: 180-9
Lazarev S, Thompson MR, Stone NN, Stock RG. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up. BJU Int 2018; 121: 781-90
Sylvester JE, Grimm PD, Wong J et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2011; 81: 376-81
Van den Broeck T, van den Bergh RCN, Arfi N et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol 2019; 75: 967-87
Parry MG, Cowling TE, Sujenthiran A et al. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation. BMC Med 2020; 18: 114